PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2075307
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2075307
Global Antisense & RNAi Therapeutics Market is estimated to be valued at USD 8.78 Bn in 2026 and is expected to reach USD 24.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.70% | 2033 Value Projection: | USD 24.37 Bn |
Antisense & RNAi therapeutics refer to a class of drugs that use naturally occurring processes to target and inhibit the expression of specific genes. They work by binding to mRNA or genomic DNA with high specificity. This inhibits the expression of disease-associated proteins. The antisense & RNAi therapeutics market is growing substantially due to its potential to treat various conditions with high specificity and few side effects. These include viral infections, cancers, genetic disorders, and others. The market is witnessing significant investments in R&D as many drug candidates are progressing through clinical trials. The development of novel drug delivery techniques is also extending the potential of antisense & RNAi therapeutics to target previously undruggable diseases.
Antisense and RNAi therapeutics are novel nucleic acid-based therapeutics designed to inhibit the expression of disease-causing genes. They work by binding to mRNA transcripts, preventing translation, or inducing mRNA degradation. This offers promise for treating various genetic disorders, cancers, and viral infections by selectively silencing unwanted genes. The technology utilizes short synthetic strands of nucleic acids such as DNA, RNA, or modified versions that are complementary to the target mRNA. The global antisense & RNAi therapeutics market is driven by the growing prevalence of various cancers, genetic disorders, and infectious diseases worldwide. RNA-targeting drugs have demonstrated safety and efficacy in clinical trials for various conditions, boosting market growth. Moreover, continuous advancements in nucleotide drug delivery systems, such as nanoparticles, have enhanced intracellular uptake of these therapeutics, expanding their clinical applications. However, high research and development costs associated with drug development and potential off-target effects are some of the challenges faced by market players. Meanwhile, the upcoming patent expiries of major brands will provide opportunities for generic versions. In addition, the development of novel RNAi drug platforms targeting chronic diseases will further stimulate market expansion.